クローン病市場分析及び予測（～2022）：世界...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 21
2 Introduction 23
2.1 Catalyst 23
2.2 Related Reports 24
2.3 Upcoming Related Reports 24
3 Disease Overview 25
3.1 Etiology and Pathophysiology 25
3.1.1 Etiology 25
3.1.2 Pathophysiology 25
3.2 Symptoms 29
3.3 Prognosis 30
3.4 Quality of Life 31
4 Epidemiology 32
4.1 Risk Factors and Comorbidities 32
4.1.1 Up to 60% of CD patients experience reduced bone density 33
4.1.2 One third of patients with CD suffer from psychiatric illness 33
4.1.3 Arthritis affects 25% of CD Patients 33
4.1.4 Gastrointestinal complications often occur as part of CD 34
4.2 Global Trends 34
4.2.1 US 35
4.2.2 5EU 36
4.2.3 Japan 37
4.2.4 Canada 38
4.2.5 China 38
4.2.6 India 39
4.3 Forecast Methodology 39
4.4 Sources Used 42
4.4.1 US 42
4.4.2 France 42
4.4.3 Germany 43
4.4.4 Italy 43
4.4.5 Spain 44
4.4.6 UK 45
4.4.7 Japan 45
4.4.8 Canada 46
4.4.9 China 46
4.4.10 India 47
4.5 Forecast Assumptions and Methods 47
4.5.1 Incident Cases 47
4.5.2 Prevalent Cases 50
4.5.3 Sources Not Used 53
4.6 Epidemiological Forecast for CD 54
4.6.1 Incident Cases of CD 54
4.6.2 Prevalent Cases of CD 59
4.7 Discussion 66
4.8 Limitations of the Analysis 68
4.9 Strengths of the Analysis 68
5 Disease Management 69
5.1 Treatment Overview 70
5.2 US 75
5.2.1 Diagnosis 75
5.2.2 Clinical Practice 75
5.3 France 77
5.3.1 Diagnosis 77
5.3.2 Clinical Practice 78
5.4 Germany 79
5.4.1 Diagnosis 79
5.4.2 Clinical Practice 79
5.5 Italy 81
5.5.1 Diagnosis 81
5.5.2 Clinical Practice 81
5.6 Spain 83
5.6.1 Diagnosis 83
5.6.2 Clinical Practice 83
5.7 UK 85
5.7.1 Diagnosis 85
5.7.2 Clinical Practice 85
5.8 Japan 87
5.8.1 Diagnosis 87
5.8.2 Clinical Practice 87
5.9 Canada 89
5.9.1 Diagnosis 89
5.9.2 Clinical Practice 89
5.10 China 90
5.10.1 Diagnosis 90
5.10.2 Clinical Practice 90
5.11 India 91
5.11.1 Diagnosis 91
5.11.2 Clinical Practice 92
6 Competitive Assessment 93
6.1 Overview 93
6.2 Strategic Competitor Assessment 94
6.3 Product Profiles – Major Brands 96
6.3.1 Remicade (infliximab) 96
6.3.2 Humira (adalimumab) 102
6.3.3 Cimzia (certolizumab pegol) 109
6.3.4 Tysabri (natalizumab) 114
6.3.5 Other Marketed Products 120
6.4 Biosimilars 121
6.4.1 Introduction 121
6.4.2 Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases 122
6.4.3 Biosimilars in the Immunology Community 123
6.4.4 By the Numbers: Biosimilars in Development 123
6.4.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 126
6.4.6 Biosimilars’ Forecast 127
7 Opportunity and Unmet Need 129
7.1 Overview 129
7.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 130
7.3 More Therapies for Anti-TNF-Refractory Patients 131
7.4 Unmet Needs Gap Analysis 132
7.5 Targeted Therapies 133
7.6 Predictive Tools for Early Diagnosis and Treatment 134
8 Pipeline Assessment 135
8.1 Overview 135
8.2 Clinical Trial Mapping 136
8.2.1 Clinical Trials by Country 136
8.3 Clinical Trials by Phase and Trial Status 137
8.4 Promising Drugs in Clinical Development 138
8.4.1 Entyvio (vedolizumab) 140
8.4.2 Stelara (ustekinumab) 152
8.4.3 Vercirnon (formerly GSK1605786) 160
8.4.4 Prochymal (Remestemcel-L) 169
8.5 Other Late-Stage Pipeline Products 175
8.5.1 Cx601 175
8.5.2 RHB-104 (clarithromycin + clofazimine + rifabutin) 178
9 Current and Future Players 182
9.1 Overview 182
9.2 Trends in Corporate Strategy 184
9.3 Company Profiles 187
9.3.1 Johnson & Johnson 187
9.3.2 AbbVie 189
9.3.3 UCB 191
9.3.4 Biogen Idec 192
9.3.5 Takeda 194
9.3.6 ChemoCentryx 196
10 Market Outlook 198
10.1 Global Markets 198
10.1.1 Forecast 198
10.1.2 Drivers and Barriers – Global Issues 202
10.2 US 207
10.2.1 Forecast 207
10.2.2 Key Events 210
10.2.3 Drivers and Barriers 210
10.3 France 214
10.3.1 Forecast 214
10.3.2 Key Events 218
10.3.3 Drivers and Barriers 218
10.4 Germany 221
10.4.1 Forecast 221
10.4.2 Key Events 225
10.4.3 Drivers and Barriers 225
10.5 Italy 228
10.5.1 Forecast 228
10.5.2 Key Events 232
10.5.3 Drivers and Barriers 232
10.6 Spain 235
10.6.1 Forecast 235
10.6.2 Key Events 239
10.6.3 Drivers and Barriers 239
10.7 UK 242
10.7.1 Forecast 242
10.7.2 Key Events 246
10.7.3 Drivers and Barriers 246
10.8 Japan 249
10.8.1 Forecast 249
10.8.2 Key Events 253
10.8.3 Drivers and Barriers 253
10.9 Canada 257
10.9.1 Forecast 257
10.9.2 Key Events 261
10.9.3 Drivers and Barriers 261
10.10 China 263
10.10.1 Forecast 263
10.10.2 Key Events 266
10.10.3 Drivers and Barriers 266
10.11 India 268
10.11.1 Forecast 268
10.11.2 Key Events 271
10.11.3 Drivers and Barriers 271
11 Appendix 274
11.1 Bibliography 274
11.2 Abbreviations 287
11.3 Methodology 291
11.4 Forecasting Methodology 291
11.4.1 Diagnosed CD Patients 291
11.4.2 Percent Drug-Treated Patients 292
11.4.3 Drugs Included in Each Therapeutic Class 292
11.4.4 Launch and Patent Expiry Dates 292
11.4.5 General Pricing Assumptions 293
11.4.6 Individual Drug Assumptions 294
11.4.7 Generic Erosion 297
11.4.8 Pricing of Pipeline agents 298
11.5 Physicians and Specialists Included in This Study 299
11.6 Primary Research – Prescriber Survey 301
11.7 About the Authors 302
11.7.1 Author/Reviewer 302
11.7.2 Epidemiologist 302
11.7.3 Global Head of Healthcare 303
11.8 About GlobalData 304
11.9 Disclaimer 304